CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,480 enrolled
Drug / intervention
Medisinstartother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02261402
NCT02261402N/ACompleted

Effectiveness of "Medisinstart" - an Open Randomized Controlled Trial of a Newly Developed Pharmacy Service

Apokus AS·interventional·Posted Oct 10, 2014·Updated Jul 20, 2021

In Brief

A clinical study evaluating Medisinstart for Cardiovascular Diseases. Completed, enrolled 1,480 participants across 67 sites.

Detailed Summary

"Medisinstart" is a new service developed for use in Norwegian pharmacies. It is intended for patients that are about to start a new medicine for a chronic or long-term condition. It is based on research showing that problems with newly prescribed medicines appear rapidly and that a significant portion of patients quickly becomes non-adherent. The service consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine. The main purpose of this study is to investigate whether "Medisinstart" increases patients' adherence to the prescribed medication. Patients' beliefs about their medicines and their motivation for adherence will also be examined. The study also aims at revealing if "Medisinstart" has additional benefits for the patient, the society and the pharmacies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesNorway

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 10, 2014
Enrollment StartOct 1, 2014
Primary CompletionDec 1, 2015
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.7 years ago

Interventions

Medisinstartother

"Medisinstart" is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.